Veterinary Medicines

Covexin 10 Suspension for injection for sheep and cattle

Authorised
  • Clostridium haemolyticum, toxoid
  • Clostridium sordellii, toxoid
  • Tetanus toxoid adsorbed
  • Clostridium septicum, toxoid
  • Clostridium novyi, toxoid
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type B and C, beta toxoid
  • Clostridium chauvoei, Inactivated
  • Clostridium perfringens, type A and C, alpha toxoid
Download as PDF

Product identification

Medicine name:
Covexin 10 Suspension for injection for sheep and cattle
COVEXIN 10, injekcinė suspensija avims ir galvijams
Active substance:
  • Clostridium haemolyticum, toxoid
  • Clostridium sordellii, toxoid
  • Tetanus toxoid adsorbed
  • Clostridium septicum, toxoid
  • Clostridium novyi, toxoid
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type B and C, beta toxoid
  • Clostridium chauvoei, Inactivated
  • Clostridium perfringens, type A and C, alpha toxoid
Target species:
  • Cattle
  • Sheep
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium haemolyticum, toxoid
    16.50
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Clostridium sordellii, toxoid
    0.80
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Tetanus toxoid adsorbed
    2.50
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Clostridium septicum, toxoid
    3.60
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Clostridium novyi, toxoid
    1.20
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type D, epsilon toxoid
    5.10
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type B and C, beta toxoid
    12.40
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Clostridium chauvoei, Inactivated
    90.00
    percentage protection
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type A and C, alpha toxoid
    0.90
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cattle
      • Milk
        0
        day
      • Meat and offal
        0
        day
    • Sheep
      • Meat and offal
        0
        day
      • Milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AB01
  • QI04AB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:
  • (ID1) 2 millilitre(s): Box (Cardboard) with 1 Bottle (High Density PolyEthylene) with 2 millilitre(s)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
  • Schering-Plough Limited
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/10/1859/002–003
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0283/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Estonia
  • France
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 4/03/2022
Download
Lithuanian (PDF)
Published on: 7/11/2023
Updated on: 11/11/2023
Download

RV1859.pdf

Lithuanian (PDF)
Published on: 26/07/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."